Overview

Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism

Status:
Completed

Trial end date:
2007-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to demonstrate the safety and effectiveness of Hectorol® (doxercalciferol) capsules in treating patients with Stage 3 or Stage 4 chronic kidney disease (CKD) with secondary hyperparathyroidism who have vitamin D levels in the normal range. Previous studies with doxercalciferol were conducted in patients who had low levels of vitamin D.

Phase:

Phase 4

Details

Lead Sponsor:

Genzyme, a Sanofi Company

Treatments:

1 alpha-hydroxyergocalciferol
Ergocalciferols